Last update 01 Nov 2024

EGFR L858R x HER2 exon 20 x EGFR T790M

Basic Info

Related Targets
EGFR L858RHER2 exon 20EGFR T790M

Related

1
Drugs associated with EGFR L858R x HER2 exon 20 x EGFR T790M
DBPR-112
Target
EGFR L858R x EGFR T790M x HER2 exon 20
Mechanism
EGFR T790M inhibitors [+2]
Active Org.
National Health Research Institutes
Originator Org.
National Health Research Institutes
Active Indication
Head and Neck Neoplasms [+1]
Inactive Indication
EGFR-mutated non-small Cell Lung Cancer
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with EGFR L858R x HER2 exon 20 x EGFR T790M
NCT03246854 / TerminatedPhase 1IIT
Phase I, Open-Label, Multiple Dose, Dose-Finding and Expansion Clinical Study to Assess the Safety, Pharmacokinetics, and Efficacy of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer
100 Clinical Results associated with EGFR L858R x HER2 exon 20 x EGFR T790M
Login to view more data
100 Translational Medicine associated with EGFR L858R x HER2 exon 20 x EGFR T790M
Login to view more data
0 Patents (Medical) associated with EGFR L858R x HER2 exon 20 x EGFR T790M
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free